2562386-85-8

2562386-85-8 structure

Name: HDAC-IN-46
Chemical Name: HDAC-IN-46
CAS Number: 2562386-85-8
Molecular Formula: C₂₂H₃₀N₈O₂
Molecular Weight: 438.53
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2022-09-13 17:53:49
Modify Date: 2025-08-25 15:25:40
HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC)[1].

Name	HDAC-IN-46

Description	HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC)[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC Signaling Pathways >> Epigenetics >> HDAC
Target	HDAC1:0.21 μM (IC50) HDAC6:0.021 μM (IC50)
In Vitro	HDAC-IN-46 (compound 12c) has antiproliferative activity against MDA-MB-231, A549 and MCF-7 with IC50s of 88.46±10.5 μM, 83.34 ± 15.5 μM and 21.4±3.7 μM, respectively[1]. HDAC-IN-46 (5, 12.5 and 25 μM; 24 h) causes concentration-dependent upregulation of p-p38 and downregulation of Bcl-xL and cyclin D1 in MDA-MB-231 cells[1]. HDAC-IN-46 (12.5 and 25 μM; 48 h) induces significant G2 phase arrest and apoptosis[1]. Western Blot Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 5, 12.5 and 25 μM Incubation Time: 24 h Result: Caused concentration-dependent upregulation of p-p38 and downregulation of Bcl-xL and cyclin D1. Cell Cycle Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 12.5 and 25 μM Incubation Time: 48 h Result: Induced significant G2 phase arrest and apoptosis.
References	[1]. Wu B, et al. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity. Bioorg Med Chem. 2020 Mar 15;28(6):115345.

Molecular Formula	C₂₂H₃₀N₈O₂
Molecular Weight	438.53

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2562386-85-8	2410542-97-9
1621154-88-8	934828-12-3
2653339-26-3	1018673-42-1
1239610-44-6	2454024-18-9
1809163-24-3	2756809-34-2
1823633-40-4	1823590-52-8
1822806-80-3	1823500-44-2
1823524-59-9	1823513-13-8
1822497-04-0	1823606-91-2
1823637-80-4	1823303-30-5